Success Story: Bioanalytical Chemistry Scientist Achieves Rapid EB-1B Approval in Just 10 Days under Premium Processing
Client’s Testimonial:
“Thank you for your great help in the process.”
On January 30th, 2026, we received another EB-1B (Outstanding Professors and Researchers) approval for a Scientist in the Field of Bioanalytical Chemistry (Approval Notice).
General Field: Bioanalytical Chemistry
Position at the Time of Case Filing: Scientist
Country of Origin: China
Approval Notice Date: January 30th, 2026
Processing Time: 10 days (Premium Processing Requested)
Case Summary:
Drawing on our extensive experience and a proven track record of over 32,000 successful cases, our expert team secured EB-1B Outstanding Researcher approval for a bioanalytical chemistry scientist whose pioneering research in mass spectrometry-based protein analysis advances critical technologies across pharmaceutical development, cancer therapeutics, and disease diagnostics.
Client Background and Expertise
With a Ph.D. in analytical chemistry, the client specializes in mass spectrometry for protein characterization, protein post-translational modifications, and developing novel separation strategies and mass spectrometry-based techniques for tackling practical challenges in bioanalytical chemistry. The proposed endeavor focuses on advancing covalent drug discovery, developing mass spectrometry workflows, mapping protein-ligand interactions, and assessing off-target effects.
Exceptional Credentials
The client’s qualifications include:
- 8 peer-reviewed journal articles (3 first-authored)
- 105 citations
- At least 30 peer reviews for highly acclaimed journals
- Major funding from the National Institute of General Medical Sciences (NIGMS) and the National Institute of Allergy and Infectious Diseases (NIAID)
The client received six recommendation letters. One independent expert stated:
“I am certain that [The Client] will continue to produce similarly impactful bioanalytical chemistry research in the years to come.”
Rapid Approval Success
With our support, the client received EB-1B approval in just 10 days under the premium process without a Request for Evidence. Currently serving as a scientist developing innovative drug discovery methodologies, the client continues advancing U.S. pharmaceutical innovation and disease research capabilities. It has been an honor to support this journey, and we extend our sincere best wishes for the client’s continued success in pioneering bioanalytical chemistry technologies and strengthening American leadership in therapeutic development.

